John Bryant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
John Bryant has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Charles E Geyer
National Surgical Adjuvant Breast and Bowel Project, East Commons Professional Building, Four Allegheny Center, 5th Floor, Pittsburgh, PA 15212, USA
1 shared publicationJames J. Dignam
1 shared publication
Latest Publications
- 1 March 2006
- Published by Elsevier in The Lancet
- Vol. 367 (9512) , 728
Trastuzumab for early breast cancer
- 1 March 2006
- Published by Elsevier in The Lancet
- Vol. 367 (9512) , 728
Trastuzumab for early breast cancer
- 27 April 2004
- Published by Wiley in Statistics in Medicine
- Vol. 23 (10) , 1507-1511
What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?
A recent draft FDA Guidance on the establishment and operation of clinical trial Data Monitoring Committees (DMCs) suggests that statisticians who prepare and present interim analyses to the DMC should be external to the trial sponsor. In the context of the National Cancer Institute (NCI) Cooperative Group program, this recommendation appears to imply that Group study statisticians should be blinded to interim data and excluded from the interim monitoring process in all Cooperative Group trials. In this commentary, it is argued that the benefits of such a policy would be minimal in the Cooperative Group setting and are far outweighed by the tangible benefits of including the study statistician in the monitoring process. Copyright 2004 John Wiley & Sons, Ltd.
- 27 April 2004
- Published by Wiley in Statistics in Medicine
- Vol. 23 (10) , 1507-1511
What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?
A recent draft FDA Guidance on the establishment and operation of clinical trial Data Monitoring Committees (DMCs) suggests that statisticians who prepare and present interim analyses to the DMC should be external to the trial sponsor. In the context of the National Cancer Institute (NCI) Cooperative Group program, this recommendation appears to imply that Group study statisticians should be blinded to interim data and excluded from the interim monitoring process in all Cooperative Group trials. In this commentary, it is argued that the benefits of such a policy would be minimal in the Cooperative Group setting and are far outweighed by the tangible benefits of including the study statistician in the monitoring process. Copyright 2004 John Wiley & Sons, Ltd.
- 11 March 2004
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 60 (1) , 182-190
Semiparametric Models for Cumulative Incidence Functions
Summary. In analyses of time‐to‐failure data with competing risks, cumulative incidence functions may be used to estimate the time‐dependent cumulative probability of failure due to specific causes. These functions are commonly estimated using nonparametric methods, but in cases where events due to the cause of primary interest are infrequent relative to other modes of failure, nonparametric methods may result in rather imprecise estimates for the corresponding subdistribution. In such cases, it may be possible to model the cause‐specific hazard of primary interest parametrically, while accounting for the other modes of failure using nonparametric estimators. The cumulative incidence estimators so obtained are simple to compute and are considerably more efficient than the usual nonparametric estimator, particularly with regard to interpolation of cumulative incidence at early or intermediate time points within the range of data used to fit the function. More surprisingly, they are often nearly as efficient as fully parametric estimators. We illustrate the utility of this approach in the analysis of patients treated for early stage breast cancer.
- 11 March 2004
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 60 (1) , 182-190
Semiparametric Models for Cumulative Incidence Functions
Summary. In analyses of time‐to‐failure data with competing risks, cumulative incidence functions may be used to estimate the time‐dependent cumulative probability of failure due to specific causes. These functions are commonly estimated using nonparametric methods, but in cases where events due to the cause of primary interest are infrequent relative to other modes of failure, nonparametric methods may result in rather imprecise estimates for the corresponding subdistribution. In such cases, it may be possible to model the cause‐specific hazard of primary interest parametrically, while accounting for the other modes of failure using nonparametric estimators. The cumulative incidence estimators so obtained are simple to compute and are considerably more efficient than the usual nonparametric estimator, particularly with regard to interpolation of cumulative incidence at early or intermediate time points within the range of data used to fit the function. More surprisingly, they are often nearly as efficient as fully parametric estimators. We illustrate the utility of this approach in the analysis of patients treated for early stage breast cancer.